STALLERGENES, a European biopharmaceutical company with an international professional commitment

The 4 commitments of STALLERGENES:

1. To continue a close partnership with the allergological community to ensure that every patient benefits from a simple, personalised therapeutic solution perfectly adapted to his or her circumstances.

The STALLERGENES group is in daily contact with physicians specializing in allergic diseases: allergists, respiratory physicians, dermatologists, paediatricians, ENT specialists, etc. Over the years, a tremendous collaboration has been developed between the allergology community and STALLERGENES, with an emphasis on transparency, sharing of knowledge and exchange of experience.

2. To continue to develop our potential in the advancement of the field of allergology and to propose new therapeutic solutions through immunotherapy.

Each year, STALLERGENES invests over 15% of financial turnover in research and development (17% in 2007). R&D has already provided important innovations that have greatly contributed to recent progress in the standardisation of allergens and in allergen immunotherapy.

3. To provide clinical evidence for the efficacy and safety of the proposed therapeutic solutions.

Regarding clinical trials, STALLERGENES is one of the most active investigators in the field of immunotherapy. All of these studies were double blind, placebo controlled and involved the enrolment of more than 2700 patients since 2000. This dynamic approach has led to recognition of the efficacy of sublingual administration by the international community.

4. To maintain and develop high quality standards in all internal processes and to undergo regular auditing to ensure compliance with the most stringent national and international quality norms.

Several years ago, STALLERGENES developed a complete process of real-time traceability of personalised prescriptions. In 1999, STALLERGENES gained European ISO 9001 certification in recognition of the quality of the company's method and production.